Canaccord Genuity raises First Tracks Biotherapeutics target price to $60 from $50
TRAX•Canaccord Genuity raised its target price for First Tracks Biotherapeutics to $60 from $50.
TRAX•TRAX•TRAX•Canaccord Genuity raised its target price for First Tracks Biotherapeutics to $60 from $50.
